FDA Accepts IND Application for Cartesian Therapeutics' Descartes-08 in Myositis
I'm PortAI, I can summarize articles.
Cartesian Therapeutics Inc. announced that the FDA has accepted its IND application for a Phase 2 clinical trial of Descartes-08 in myositis. The trial will assess the safety and efficacy of Descartes-08 in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome, starting in the first half of 2026. This approval allows for a randomized, double-blind, placebo-controlled trial, with potential for a seamless transition to a pivotal study based on interim results.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments